Key points are not available for this paper at this time.
Design
Review
May support dual-purpose anti-inflammatory therapies; leaves open whether they improve cardiometabolic or bone outcomes in practice.
Accumulating evidence indicates that the several components of the cardiometabolic syndrome such as hypertension, increased triglycerides, and reduced high-density lipoprotein cholesterol are also risk factors for low bone mineral density. Furthermore, some of the underlying risk factors for atherosclerosis in the cardiometabolic syndrome, such as inflammation, also play a major role in the pathogenesis of osteoporosis, the most common metabolic bone disease. In this article for the premiere issue of the Journal of the CardioMetabolic Syndrome, the author presents the current evidence of the interaction of bone metabolism and the cardiometabolic syndrome, highlighting the major research in this area and discussing the potential of therapeutic agents that will be useful in the treatment of osteoporosis as well as atherosclerosis.
No takes yet. Share an insight, caveat, or question.
Samy I. McFarlane (2006) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: